ClinicalTrials.Veeva

Menu

Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation

H

Hannover Medical School (MHH)

Status

Terminated

Conditions

Bronchiolitis Obliterans

Treatments

Procedure: photopheresis

Study type

Interventional

Funder types

Other
Industry

Identifiers

Details and patient eligibility

About

Investigation of photopheresis as new therapy regimen in patients with bronchiolitis obliterans syndrome after lung transplantation in a controlled, randomized study

Full description

Bronchiolitis obliterans syndrome is the major cause of mortality after lung transplantation. 5 years after lung transplantation about 50% of all patients have this syndrome. There are nearly none therapy options. Besides effective therapy of any gastrooesophageal reflux and an oral medication with azithromycin none further regimens are known. Photopheresis could show in several studies a benefit for patients with gvhd after bone marrow transplantation or for chronic rejection after any other solid organ transplantation. Just little case reports could show beneficial effect in patients with bos after lung transplantation.

This is the first controlled, randomized study with patients with bos after lung transplantation to investigate the effectiveness of this therapy in that patients.

Enrollment

12 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Single/Double lung transplantation
  • at least 6 months after lung transplantation
  • bronchiolitis obliterans syndrome, Stadium > 1 (nach ISHLT 2001, FEV1 <80% Best), none other reason for worsening lung function (eg acute rejection, infection, extrapulmonary reasons, airway obstruction)
  • none gastroesophageal reflux
  • medication for > 3 months with Azithromycin with further decrease of FEV1, MEF 25-75
  • bioptic prove that there is no acute rejection
  • no improvement under steroid pulse therapy

Exclusion criteria

  • tumor or hematologic disease
  • acute rejection
  • respiratory insufficiency (O2>2l/min, pCO2 >50 mm Hg)
  • weight < 40 kg
  • acute infection
  • colonization with multiresistant pathogens

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

12 participants in 2 patient groups

1
No Intervention group
Description:
Observation with standard care (macrolides, exercise, oxygen therapy etc.) alone.
Treatment:
Procedure: photopheresis
2
Active Comparator group
Description:
2-day cycles of photopheresis every 3 weeks for 3 months
Treatment:
Procedure: photopheresis

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems